Dupixent (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis Read more
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 Read more
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs Read more
Syneos Health Collaborates with Microsoft to Accelerate AI Across the Clinical to Commercial Continuum Read more
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications Read more
Hovione and Ripple Enter Strategic Partnership to Expand Epidel Platform into Non-Ophthalmic Space Read more
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP Read more